Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Carrageenin in-situ forming gel spray for noses, and preparation method of carrageenin in-situ forming gel spray for noses

A technology of spray and carrageenan, which is applied in the field of medicine, can solve the problems of inconvenient use of nasal administration and irritation of nasal mucosa, etc., and achieve the effect of enhancing the ability to prevent respiratory infectious diseases, enhancing stimulation, and preventing syneresis

Pending Publication Date: 2020-07-24
瑞希(重庆)生物科技有限公司
View PDF6 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among them, the temperature-sensitive instant gel needs to be refrigerated, and it is inconvenient to use as nasal administration; the pH-sensitive instant gel is highly acidic and will irritate the nasal mucosa

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Carrageenin in-situ forming gel spray for noses, and preparation method of carrageenin in-situ forming gel spray for noses
  • Carrageenin in-situ forming gel spray for noses, and preparation method of carrageenin in-situ forming gel spray for noses
  • Carrageenin in-situ forming gel spray for noses, and preparation method of carrageenin in-situ forming gel spray for noses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] A carrageenan nasal instant gel spray, by weight percentage, the gel spray comprises the following components: 6% of κ-type carrageenan with a molecular weight of 30k, 4% of iota-type carrageenan with a molecular weight of 30k, 0.001% of λ-type carrageenan with a molecular weight of 20k, 1% of antiviral drug (interferon), acceptable excipients in external skin preparations (suspending agent [xanthan gum] 0.3%, wetting agent [glycerin] 10%, Preservative [chlorobutanol] 0.3%, pH adjuster [sodium hydroxide, hydrochloric acid]) 10.6%, and the balance is deionized water. This gel spray is prepared as follows:

[0025] The κ-type carrageenan with a molecular weight of 30k, the iota-type carrageenan with a molecular weight of 30k, the lambda-type carrageenan with a molecular weight of 20k, antiviral drugs (interferon), and acceptable adjuvant (suspending agent [yellow] Raw gum], wetting agent [glycerin], preservative [chlorobutanol]) are added to deionized water, mixed well a...

Embodiment 2

[0027] A carrageenan nasal instant gel spray, by weight percentage, the gel spray comprises the following components: 7% of κ-type carrageenan with a molecular weight of 20k, 3% of iota-type carrageenan with a molecular weight of 40k, Molecular weight is 0.005% of lambda type carrageenan of 10k, antiviral drug (amantadine hydrochloride) 1%, acceptable adjuvant (suspending agent [carboxymethylcellulose sodium] 5%, wetting agent [ Tween 60] 8%, preservative [ethylparaben] 0.3%, pH regulator [ethanolamine, citric acid]) 13.3%, and the balance is deionized water. This gel spray is prepared as follows:

[0028] The κ-type carrageenan with a molecular weight of 20k, the iota-type carrageenan with a molecular weight of 40k, the λ-type carrageenan with a molecular weight of 10k, antiviral drugs (amantadine hydrochloride), acceptable adjuvant (suspension agent) in external skin preparations [Sodium carboxymethylcellulose], wetting agent [Tween 60], preservative [ethylparaben]) are add...

Embodiment 3

[0030] A carrageenan nose instant gel spray, by weight percentage, the gel spray comprises the following components: 5% of κ-type carrageenan with a molecular weight of 40k, 5% of iota-type carrageenan with a molecular weight of 20k, 0.001% of λ-type carrageenan with a molecular weight of 10k, 1.5% of antiviral drug (Ateclovir), acceptable adjuvant in skin topical preparations (suspending agent [Carbopol] 5%, wetting agent [ethanol] 5% %, preservative [potassium sorbate] 1%, pH regulator [ethylenediamine, sorbic acid]) 11%, and the balance is deionized water. This gel spray is prepared as follows:

[0031] The κ-type carrageenan with a molecular weight of 40k, the iota-type carrageenan with a molecular weight of 20k, the λ-type carrageenan with a molecular weight of 10k, antiviral drugs (ateclovir), acceptable adjuvant (suspension agent) in skin external preparations [Carbopol], wetting agent [ethanol], preservative [potassium sorbate]) into deionized water, mix well and add ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Molecular weightaaaaaaaaaa
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to a carrageenin in-situ forming gel spray for noses, and a preparation method of the carrageenin in-situ forming gel spray for noses, and belongs to the technical field of medicine and pharmacy. The gel spray comprises the following components in percentage by weight: 5-7% of kappa type carrageenin, 3-5% of iot type carrageenin, 0.001-0.005% of lambda type carrageenin, 5-16%of acceptable auxiliary materials in an external preparation for skin, and the balance water. Firstly, through regulating the consumption ratio of the kappa type carrageenin to the iot type carrageenin, the proportion of sulfuric ester content in a mixture is changed, when the gel spray is sprayed into the noses, the elasticity of gel can be improved through potassium ions and calcium ions in nasal cavity secretions, and besides, synaeresis of the gel can also be prevented. An inflammatory reaction is activated through an appropriate amount of the lambda type carrageenin, and human body localimmunization capacity substances are activated to form a layer of film on the surface of a nasal cavity, so that a virus infection way is blocked, and infection of respiration diseases is prevented.The gel spray is simple in preparation method, easy to operate, low in equipment requirements and suitable for large-scale production.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a carrageenan instant gel spray for nasal use and a preparation method thereof. Background technique [0002] On April 24, 2003, the State Food and Drug Administration approved the recombinant human interferon A2b spray to be used in clinical observation of high-risk groups to prevent atypical pneumonia. Preliminary tests have proved that interferon is administered through the nasal cavity and directly acts on the respiratory mucosa. By activating receptors located on the nasal mucosa and surrounding lymphoid tissue, it directly acts on the immune system, making the cells on the surface of the respiratory mucosa quickly enter an antiviral state, thereby effectively blocking respiratory virus infection. In addition, interferon can also be inhaled through the nasal cavity to regulate the immune function of the body and have a certain effect on blocking the way of respi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/70A61K9/12A61K45/00A61K31/13A61K31/215A61K31/351A61K31/431A61K31/513A61K31/522A61K31/5383A61K31/675A61K31/7048A61K31/7052A61K31/7056A61K47/36A61P31/02A61P31/16A61P31/14
CPCA61K9/0043A61K9/7015A61K45/00A61K31/13A61K31/351A61K31/215A61K31/522A61K31/7056A61K31/675A61K31/513A61K31/431A61K31/7052A61K31/7048A61K31/5383A61K47/36A61P31/02A61P31/16A61P31/14A61K2300/00
Inventor 冯文学李杨洪
Owner 瑞希(重庆)生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com